Ee11-Immune-mediated Skin Diseases (Emerging)
Epidemiology and Public Health / IBS-Ee11 / Emerging
It is a multidisciplinary group in which different professional categories and medical specialists intervene with a care and teaching nature. Currently the research work is focused on aspects related to ECCE in phase III of new biological therapies for the treatment of immune-mediated diseases and measurement of results in health and quality of life of the different patients object of the clinical series in which they intervene the members of the research group.
Research lines
- Quality of life in the elderly population
- Geriatric dermatology
- Nonmelanoma and melanoma skin cancer epidemiology
- Lifestyles and health
- Psoriasis and IMIDS. Atopic dermatitis
MARTA CEBOLLA VERDUGO
Alvaro Prados Carmona
ANGELA AYEN RODRIGUEZ
HUSEIN HUSEIN EL-AHMED
FRANCISCO JOSE NAVARRO TRIVIÑO
TERESA RODENAS HERRANZ
LAURA LINARES GONZALEZ
RICARDO RUIZ VILLAVERDE
GONZALO RUIZ VILLAVERDE
Black-purplish nodules on skin: a time-sensitive finding
JOURNAL OF THE DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024;
FI: 5,6; D1
Acne keloidalis nuchae: An international multicentric review of 79 patients
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024;
FI: 8,5; D1
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024;
FI: 8,5; D1
If not angioedema, what is it? Diagnostic approach to facial edema
JOURNAL OF THE DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024;
FI: 5,6; D1
Genetic Association and Differential RNA Expression of Histone (De)Acetylation-Related Genes in Pemphigus Foliaceus-A Possible Epigenetic Effect in the Autoimmune Response
LIFE-BASEL, 2024;
FI: 3,2; Q1
Radiation dermatitis in a patient treated for hepatocarcinoma
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2023;
FI: 17,4; D1
Is Roflumilast eine geeignete Alternative zur Behandlung des lichen planus?
JOURNAL OF THE DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023;
FI: 3,9; Q1
Multiple Minute Digitate Hyperkeratosis: 10 Years in Caccettas Algorithmus. Fallbericht und narrative Übersicht
JOURNAL OF THE DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023;
FI: 3,9; Q1
Frontal Fibrosing Alopecia: An Observational Single-Center Study of 306 Cases
LIFE-BASEL, 2023;
FI: 3,2; Q2
Lichenoid drug eruption induced by pravastatin; is it possible to prescribe other statins?
BRAZILIAN ANAIS OF DERMATOLOGY, 2023;
FI: 1,7; Q3
Acrokeratosis verruciformis of Hopf: dermoscopy approach in dark skin patients
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022;
FI: 9,228; D1
Cutaneous leishmaniasis over a tattoo mimicking keratoacanthoma in Southern Europe
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022;
FI: 9,228; D1
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
BRITISH JOURNAL OF DERMATOLOGY, 2022;
FI: 11,113; D1
Dermo-cosmetic spray containing Rhealba oat plantlets and Uncaria tomentosa extract in patients with mild-to-moderate cutaneous pain
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022;
FI: 9,228; D1
Allergic contact dermatitis caused by Intrasite Conformable and Cutimed Sorbact wound dressings
CONTACT DERMATITIS, 2022;
FI: 6,419; Q2
Acute localized exanthematous pustulosis (ALEP) induced by iomeprol (Iomeron 350): A diagnostic challenge
CONTACT DERMATITIS, 2021;
FI: 6,6; D1
Airborne allergic contact dermatitis caused by spirotetramat (Movento 150 (R))
CONTACT DERMATITIS, 2021;
FI: 6,6; D1
A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?
LIFE-BASEL, 2021;
FI: 3,817; Q2
104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain
BRAZILIAN ANAIS OF DERMATOLOGY, 2021;
FI: 1,896; Q3
A skin ulcer may be a clue to rule out the Blue Whale Challenge
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021;
FI: 2,736; Q3
Flower and Milium: A Tattoo With Points in Relief
DERMO-SYFILIOGRAPHIC ACTS, 2020;
A Microservices e-Health System for Ecological Frailty Assessment Using Wearables
SENSORS, 2020;
FI: 3,275; Q1
Acrylate allergic contact dermatitis caused by hair prosthesis fixative
CONTACT DERMATITIS, 2020;
FI: 3,952; Q1
Allergic contact dermatitis caused by caprylic / capric triglyceride from an anti-aging cosmetic cream
CONTACT DERMATITIS, 2020;
FI: 3,952; Q1
Expression of IMP3 in a retrospective cohort of melanomas with selective lymph node biopsy
DERMATOLOGICAL THERAPY, 2020;
FI: 2,327; Q2
Dupilumab: short-term effectiveness and security in real clinical practice - A retrospective multicentric study
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019;
FI: 5,113; D1
Eugenol allergy mimicking recurrent aphthous stomatitis and burning mouth syndrome
CONTACT DERMATITIS, 2019;
FI: 5,504; D1
Sexual Distress in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study
JOURNAL OF CLINICAL MEDICINE, 2019;
FI: 5,688; D1
sQUIZ your knowledge! Polycyclic annular plaques on the back of an elderly patient Annular elastolytic giant cell granuloma
EUROPEAN JOURNAL OF DERMATOLOGY, 2019;
FI: 3,094; Q1
sQUIZ your knowledge! A painful nodule on the forehead of an elderly patient
EUROPEAN JOURNAL OF DERMATOLOGY, 2019;
FI: 3,094; Q1
Phaeohyphomycosis due to Pleurostomophora richardsiae: an uncommon cutaneous fungal infection
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018;
FI: 4,287; Q1
Effectiveness of two home ergonomic programs in reducing pain and enhancing quality of life in informal caregivers of post-stroke patients: A pilot randomized controlled clinical trial
DISABILITY AND HEALTH JOURNAL, 2018;
FI: 1,863; Q1
Google search trends in psoriasis: a pilot evaluation of global population interests
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018;
FI: 4,287; Q1
Evaluation of Functional Status Associated With Overweight in Adults With Cerebral Palsy
REHABILITATION NURSING, 2018;
FI: 1,351; Q2
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
JOURNAL OF DERMATOLOGICAL TREATMENT, 2018;
FI: 2,144; Q2
History, clinical findings, and histopathology Vulvar steatocystoma multiplex
JOURNAL OF THE DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017;
FI: 2,865; Q1
Smoothelin and WT-1 expression in glomus tumors and glomuvenous malformations
HISTOLOGY AND HISTOPATHOLOGY, 2017;
FI: 2,025; Q2
CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS)
CLINICAL GENETICS, 2017;
FI: 3,326; Q2
Bilateral plantar geographic injuries
JOURNAL OF PEDIATRICS AND CHILD HEALTH, 2017;
FI: 1,572; Q3
Beyond Urticaria: Schnitzler Syndrome
BALKAN MEDICAL JOURNAL, 2017;
FI: 1,083; Q3
Yellowish Papules on the Palms After Water Immersion
MAYO CLINIC PROCEEDINGS, 2016;
FI: 5,92; D1
Terra firma-form dermatosis
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2016;
FI: 6,724; D1
Reply to: idiopathic «Half and half' nails
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016;
FI: 3,029; Q1
Effectiveness of a flamenco and sevillanas program to enhance mobility, balance, physical activity, blood pressure, body mass, and quality of life in postmenopausal women living in the community in Spain: a randomized clinical trial
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016;
FI: 3,172; Q1
Health-Related Quality of Life, Gender, and Culture of Older People Users of Health Services in the Multicultural Landscape of the City of Ceuta (Spain): A Cross-Sectional Study
JOURNAL OF TRANSCULTURAL NURSING, 2016;
FI: 1,111; Q2
CLINICAL IMAGES Pitted keratolysis: an infective cause of foot odor
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2015;
FI: 5,959; D1
In reply-Cutaneous and Uterine Leiomyomas
MAYO CLINIC PROCEEDINGS, 2015;
FI: 6,262; D1
Multiple Painful Nodules and Uterine Leiomyomas
MAYO CLINIC PROCEEDINGS, 2015;
FI: 6,262; D1
Unusual Erythematous and Infiltrated Plaque
AMERICAN FAMILY PHYSICIAN, 2015;
FI: 2,175; Q1
Should arm span or height be used in calculating the BMI for the older people? Preliminary results
JOURNAL OF CLINICAL NURSING, 2015;
FI: 1,255; Q2
A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 30/09/2024 - 17/06/2026
PI: RICARDO RUIZ VILLAVERDE
A 48-week, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III extension study to evaluate the treatment response and safety of two dosage regimens of amlitelimab administered as monotherapy by subcutaneous injection in participants 12 years of age and older with moderate to severe atopic dermatitis.
Financier: SANOFI-AVENTIS, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 15/05/2024 - 13/10/2026
PI: RICARDO RUIZ VILLAVERDE
A phase III, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants 12 years of age and older with moderate to severe atopic dermatitis receiving background topical corticosteroid therapy.
Financier: SANOFI-AVENTIS, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 27/05/2024 - 30/06/2026
PI: RICARDO RUIZ VILLAVERDE
Efficacy and safety of lebrikizumab treatment in adults and adolescents with moderate to severe atopic dermatitis.
Funder: ICON CLINICAL RESEARCH LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 20/05/2024 - 17/07/2026
PI: RICARDO RUIZ VILLAVERDE
Long-term extension study (AtDvance) to evaluate the safety and efficacy of GSK1070806 in participants with moderate to severe atopic dermatitis.
Funder: GLAXOSMITHKLINE, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 01/10/2024 - 30/05/2030
PI: RICARDO RUIZ VILLAVERDE
Lunsayil LTE: Extension study to evaluate long-term treatment with espesolimab in patients with hidradenitis suppurativa (HS).
Financier: BOEHRINGER INGELHEIM ESPAÑA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 30/04/2024 - 30/09/2030
PI: RICARDO RUIZ VILLAVERDE
A phase 2b randomized, double-blind, parallel-group, placebo-controlled, dose-finding study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 administered by subcutaneous injection in adult participants with moderate to severe atopic dermatitis.
Funder: GLAXOSMITHKLINE, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 06/12/2023 - 30/10/2025
PI: RICARDO RUIZ VILLAVERDE
BIOBADATOP Spanish Registry of Atopic Dermatitis.
Funder: HEALTHY SKIN FOUNDATION OF THE SPANISH ACADEMY OF DERMATOLOGY
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 18/09/2023 - 30/08/2033
PI: RICARDO RUIZ VILLAVERDE
Biobadaderm: Spanish Registry of Systemic Treatments for Psoriasis.
Funder: HEALTHY SKIN FOUNDATION OF THE SPANISH ACADEMY OF DERMATOLOGY
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 18/09/2023 - 30/08/2028
PI: RICARDO RUIZ VILLAVERDE
A randomized, single-blind (rater)-blind, parallel-group monotherapy trial to evaluate the pharmacokinetics and safety of tralokinumab in children (2 to <12 years) with moderate to severe atopic dermatitis. TRAPEDS 1
Funder: LEO PHARMA A / S
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 18/01/2023 - 30/03/2026
PI: RICARDO RUIZ VILLAVERDE
Randomized, double-blind, placebo-controlled phase IIb/III study to evaluate the efficacy and safety of espesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
Financier: BOEHRINGER INGELHEIM ESPAÑA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 13/03/2023 - 30/09/2028
PI: RICARDO RUIZ VILLAVERDE
Phase 3b, interventional, adaptive clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every two weeks as monotherapy compared to placebo in subjects with moderate to severe atopic hand eczema who are candidates
Funder: LEO PHARMA A / S
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 13/07/2023 - 30/03/2027
IP: FRANCISCO JOSE NAVARRO TRIVIÑO
Non-interventional multicenter study to characterize the clinical characteristics, disease burden and unmet medical needs of patients with generalized pustular psoriasis (GPP) in Spain. IMPULSE study.
Financier: BOEHRINGER INGELHEIM ESPAÑA, SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 03/12/2021 - 30/05/2022
PI: RICARDO RUIZ VILLAVERDE
Results in real clinical practice of treatment in patients with moderate-severe atopic dermatitis
Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE
Test type: REST OF EEOO WITH MEDICATIONS
Execution time: 30/06/2022 - 30/12/2024
PI: RICARDO RUIZ VILLAVERDE
Phase III clinical trial to evaluate the efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared to a carrier cream in adolescents 12 to 17 years of age with moderate to severe chronic hand eczema.
Funder: LEO PHARMA A / S
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 27/06/2022 - 30/10/2023
IP: FRANCISCO JOSE NAVARRO TRIVIÑO
TRACE. Real-Life Clinical Use of Tralokinumab Observational Cohort Study of Patients With Atopic Dermatitis Prescribed Tralokinumab
Funder: LEO PHARMA A / S
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 09/11/2022 - 30/12/2024
PI: RICARDO RUIZ VILLAVERDE
Cross-sectional observational study to assess the impact of chronic urticaria from the patient's perspective. CHRONIC URTICARIA ATLAS SURVEY
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 27/05/2021 - 30/11/2021
PI: RICARDO RUIZ VILLAVERDE
Prospective Observational Study with adult patients receiving treatment with Dupixent for atopic dermatitis. OBS15990
Financer: SANOFI AVENTIS GROUP
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 29/06/2021 - 30/09/2026
PI: RICARDO RUIZ VILLAVERDE
Global cross-sectional study of the burden of disease in adolescent and adult patients with atopic dermatitis (MEASURE AD)
Funder: ABBVIE SPAIN SLU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 19/03/2020 - 30/09/2020
PI: RICARDO RUIZ VILLAVERDE
